Phase 3 MASLD master protocol (NCT07165028, see Retatrutide and fatty liver): multi-agent MASLD program that includes retatrutide not a dedicated retatrutide-only liver trial
Key Takeaways MedVi charges $199$299/month for compounded GLP-1 medications through its online telehealth platform, with no insurance accepted Several alternatives cost less: Enhance.MD starts at $49 for the first month, Yucca Health from $169/month, and T-Mates offers no-hidden-fee flat pricing Insurance-friendly options exist: Found Health (free insurance check) and PlushCare work with health insurance, potentially saving $50$200+/month All providers offer compounded or brand-name GLP-1s: Semaglutide and tirzepatide are the most commonly prescribed across platforms Research-grade peptides offer another path: For laboratory and research use, GLP-1 compounds are available at significantly lower cost MedVi has grown into one of the more visible telehealth platforms for GLP-1 weight loss prescriptions, serving over 500,000 patients through its online portal and generating $1.6 billion in first-year sales
The FDA recently approved two products that combine basal insulin with a GLP-1 RA in one pen device
Looking at the bigger picture can help you spot what might be affecting your progress
Ordering decisions should be based on the medication name, active ingredient, strength, and tablet count
.jpg)
